NFKB1 and neoplasm: Of note, tumor cell clearance via increased phagocytosis, as seen with Ab or CAR in vitro, is not likely the predominant mechanism of p50-IMC efficacy in vivo, given the small numbers of p50-IMC that reach tumor (~ 2% of tumor myeloid cells in the B6CaP model) and the dependence of anti-tumor efficacy on T cell activation [8].